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Healthcare settings have played a major role in propagation of Ebola virus (EBOV) outbreaks. Healthcare workers (HCWs) have elevated 
risk of contact with EBOV-infected patients, particularly if safety precautions are not rigorously practiced. We conducted a serosur-
vey to determine seroprevalence against multiple EBOV antigens among HCWs of Boende Health Zone, Democratic Republic of the 
Congo, the site of a 2014 EBOV outbreak. Interviews and specimens were collected from 565 consenting HCWs. Overall, 234 (41.4%) of 
enrolled HCWs were reactive to at least 1 EBOV protein: 159 (28.1%) were seroreactive for anti-glycoprotein immunoglobulin G (IgG), 
89 (15.8%) were seroreactive for anti-nucleoprotein IgG, and 54 (9.5%) were VP40 positive. Additionally, sera from 16 (2.8%) HCWs 
demonstrated neutralization capacity. These data demonstrate that a significant proportion of HCWs have the ability to neutralize virus, 
despite never having developed Ebola virus disease symptoms, highlighting an important and poorly documented aspect of EBOV infec-
tion and progression.
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Outbreaks of Ebola virus disease (EVD) represent a major public 
health challenge in sub-Saharan Africa. EVD was initially rec-
ognized in 1976 during simultaneous outbreaks in Zaïre (now 
Democratic Republic of the Congo [DRC]) (Zaïre ebolavirus 
[EBOV]) and Sudan (Sudan ebolavirus) [1, 2]. Since then, there 
have been >37 EVD outbreaks spanning 14 different countries in 
Africa, Europe, Asia, and North America, with the majority caused 
by EBOV, 8 of which (including an outbreak that is currently 
unfolding at the time of manuscript submission, May 2018) have 
occurred in the DRC [3]. During these outbreaks, there was 
increased infection and deaths among those healthcare workers 
(HCWs) charged with the responsibility of caring for those suffer-
ing with EVD, a contributing factor to outbreak progression [4].
Healthcare workers are on the front line of patient care, and 
thus at increased risk of disease acquisition due to occupational 
exposures to bodily fluids, lack of infection control training, and 
a dearth of personal protective equipment. Human-to-human 
transmission of ebolavirus occurs through direct contact with 
bodily fluids (vomit, diarrhea), secretions, or blood of infected 
people via broken skin or mucous membranes; it may also be 
transmitted through contact with contaminated surfaces and 
materials (eg, bedding, clothing) [5–9]. This risk is even greater in 
limited resource settings of sub-Saharan Africa and has been doc-
umented in several studies assessing the seroprevalence of blood-
borne pathogens in these populations [10–13]. Historically, 
HCWs have perpetuated the spread and amplification of EVD 
and serve as axes of viral transmission, often before ebolavirus 
is even recognized as the causative agent [14–21]. The symptoms 
of EVD are frequently nonspecific, characterized by fever, head-
ache, fatigue, muscle pain, vomiting, diarrhea, and abdominal 
pain [22], and can easily be confused with other endemic diseases 
such as typhoid or malaria [23]. The difficulties associated with 
clinical recognition and diagnostic capabilities make prevention 
efforts for HCWs complex because infected workers may trans-
mit disease before any symptoms are accurately diagnosed.
Despite HCWs’ increased risk of acquiring and transmitting 
the disease, there is limited research assessing the total burden of 
ebolavirus among HCWs [10, 15–18, 24]. Understanding sero-
logic responses in high-risk populations, such as HCWs, and 
determining overall seroprevalence in areas with previous EVD 
outbreaks may provide more information on exposure. Current 
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literature on HCWs and serological testing for ebolaviruses (for 
evidence of exposure) is restricted mainly to anti-glycoprotein 
(GP) antibody, the viral protein critical for attachment to and 
penetration of host cells. Because of its positioning on the virion 
surface, GP is a target of neutralizing antibodies and has been 
frequently studied as a target for vaccines and other therapeutics 
[22, 25–27]. Furthermore, Richardson et al suggest limiting the 
definition of EBOV seropositivity to anti-GP reactivity based on 
a comparison of anti-GP and anti-nucleoprotein (NP) antibody 
responses [28]. However, a separate experiment by Becquart and 
colleagues in 2014, comparing sera from asymptomatic sero-
positive individuals to symptomatic survivors of EVD, showed 
that immunoglobulin G (IgG) responses were qualitatively dif-
ferent in each group: The asymptomatic group displayed a larger 
response to EBOV matrix protein (VP40), whereas the survivors 
had greater IgG responses to GP [29]. These findings indicate 
that anti-GP alone may not be sufficient as a marker for demon-
stration of previous exposure, especially in asymptomatically 
infected or otherwise unrecognized EVD survivors.
Here, we report the results of a serological survey of a sample 
of HCWs living in or near Boende, DRC, the site of an EVD 
outbreak that occurred 1  year prior to sample collection, in 
which at least 8 of the 68 (14%) reported cases were HCWs. We 
paired epidemiologic data with serologic detection of EBOV GP, 
anti-NP, and VP40, as well as microneutralization using EBOV 
pseudovirions to assess the presence of a range of anti-ebolavi-
rus antibodies in this high-risk population.
METHODS
Enrollment
From September to November 2015, we conducted a serosurvey 
in the Boende health zone, located 1200 km to the northwest of 
Kinshasa (capital of DRC) in the province of Tshuapa (Figure 1). 
All individuals who met the eligibility criteria (>18 years old, 
healthy [no fever or other illness reported at time of enroll-
ment], and working in a health facility, and reported being 
actively involved during the 2014 Boende outbreak response) 
were approached for enrollment in the study. All participants 
were screened for signs of current illness or fever; no partic-
ipants included in the current analysis reported ever having 
been or suspected of having been infected with EBOV. In total, 
565 HCWs were consented and enrolled in the study from 26 
health facilities (hospitals, health centers, or health posts), and 
1 church, which provided health services to the community. 
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Figure  1. Health facility locations of surveyed healthcare workers in Boende health zone, Tshuapa province, Democratic Republic of the Congo. Abbreviation: HCW, 
healthcare worker.
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The study included a sociodemographic and epidemiologic 
questionnaire and sample collection. Blood specimens fro-
zen, stored and tested were obtained from all consenting par-
ticipants by venipuncture into red-top Vacutainer tubes (BD 
Biosciences). After processing, aliquots of serum were frozen 
and stored at the Institut National de Recherche Biomedicale in 
Kinshasa and shipped to the Blood Systems Research Institute 
in San Francisco, California, for performance of the remaining 
serological and neutralization assays.
Healthcare Worker Classification
Classifications were based on the World Health Organization 
system of classification [14, 30]. “Formal HCWs” were defined 
as individuals who work in health services. This includes clinical 
staff (physicians, nurses, and laboratory staff) and administra-
tive workers in a hospital or health center, including cleaners, 
drivers, security, and community health workers. “Informal 
HCWs” were defined as traditional healers, pastors, and other 
nontraditional individuals providing care. HCWs were classified 
by their potential exposure to patients based on their reported 
occupation. “Direct contact” was defined as any HCW who had 
direct contact with sick patients and included doctors, nurses, 
and traditional healers. “Indirect contact” was defined as any 
HCW who did not have direct contact with sick patients, but 
had contact with biologic specimens, patient materials, or family 
members of sick patients (eg, laboratory technicians and room 
cleaners). “Unlikely contact” was defined as any HCW who was 
unlikely to have contact with sick patients and included posi-
tions such as hospital guards and administrators, and those with 
other classifications not related to patient care (Table 1).
Serological Testing
Enzyme-Linked Immunosorbent Assays
Human anti-EBOV GP IgG and anti-EBOV NP IgG titers were 
measured using commercially available enzyme-linked immu-
nosorbent assay (ELISA) kits (Alpha Diagnostic International) 
following the manufacturer’s protocol. The methodology has 
been described elsewhere [31]. Based on the manufacturer’s cal-
ibration, a sample was classified as mildly reactive if the serum 
antibody concentration was >1.0 units/mL control calibrator, 
and reactive if the titer was >2.5 units/mL. For analysis, we only 
include those who were considered reactive (>2.5 units/mL).
VP40 Reactivity via Luciferase Immunoprecipitation System
The C-terminal domain of EBOV VP40 (base pairs 583–981) 
was cloned into the pRen2 plasmid and transfected into Cos-1 
cells generating Renilla luciferase antigen fusion proteins. Cell 
lysates were harvested and used in immunoprecipitation assays 
with protein A/G–conjugated agarose beads and test serum 
diluted 1:100 as described by Burbelo et  al [32]. The testing 
procedure has been described elsewhere [31]. VP40 reactivity 
was determined if the relative luciferase signal postimmuno-
precipitation was at least 3 standard deviations greater than the 
background signal, as determined from a mean of 8 previously 
identified VP40-seronegative samples [31].
Table 1. Categorization of Healthcare Workers by Patient Contact Using Occupation Group Among Respondents From Boende, Democratic Republic of 
the Congo
Patient Contacta Occupation Group English Entries From Survey French Entries From Survey
Direct Nurse Nurse, supervisor Nurse (titulaire or supervisor), infirmier, chef de service, 
anesthesiste
Physician Physician Physician
Educational HCW Student, teacher Infirmiere en perfectionnement
Midwife Midwife Sage femme, matronne
Red cross Paramedic, burial team Croix rouge, secouriste
Traditional healer Traditional healer Tradipraticien(ne), guerrisseur, visionnaire des esprits
Pastor Pastor Pasteur, prier pour les malades
Indirect Pharmacy Pharmacist Pharmacien(ne), préposée a la pharmacie
Room attendant Room attendant Fille de salle, garçon de salle, intendant poste de sante
Laboratory technician Laboratory technician Laborantin, technicien(ne) de labo, microscopiste
Hygiene/housekeeping Hygienic service Hygiène et assainissement, désinfecter, assainissement
Communication Communication Relais communautaire, assistant humanitaire
Surveillance Epidemiologist Agent de surveillance, surveillance de la maladie, 
recherche active des cas, veterinaire
Unlikely Guard Sentinel Sentinelle, garde, gardien, observateur
Driver Driver Conducteur, chauffeur
Maintenance Maintenance Mecanicien
HCW (admin) Administration Administrateur, admnistratif, réceptionniste, secrétaire, 
caissier
Ordinary worker … Travailleur ordinaire, TO
Abbreviation: HCW, healthcare worker.
aAssumed level of patient contact derived from occupation group.
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Neutralization Assay
EBOV GP–bearing human immunodeficiency virus pseudo-
type viruses were generated as described previously [33], and 
pseudotype virus neutralization assays were performed [31, 34, 
35]. Infection rates in presence of human serum samples were 
expressed as percentage of infection in presence of negative 
control serum. To be considered neutralizing, serum from the 
patients had to at least neutralize approximately 50% of virus at 
a dilution of 1:50 compared to appropriate control.
Data Analysis
Results from the multiple assays were compared to explore 
the overlap between EBOV seroreactivity. We ran cross-tabu-
lations on all sociodemographic factors and reported occupa-
tion to explore descriptive characteristics of the population and 
compared these factors to their seroprevalence for each assay. 
We assessed differences in factors using χ2 or Fisher exact test. 
Sensitivity analyses were conducted by including mildly reac-
tive antibody titers with the reactive antibody titers. All anal-
yses were completed using R 3.4.2 and SAS version 9.4 (SAS 
Institute) software.
Ethical Approval
Ethical approval was obtained from the institutional review 
boards at the University of California, Los Angeles Fielding 
School of Public Health and the Kinshasa School of Public 
Health, DRC.
RESULTS
Participant Characteristics
Among the 565 HCWs, 370 (65.5%) were male and 195 (34.5%) 
were female (Table 2). The median age of HCWs was 40 years 
(interquartile range, 31.8–50  years). More than half (363 
[64.2%]) of participants worked in a health facility, includ-
ing the general hospital, health centers, and health posts, and 
61 (10.8%) reported working in other facilities, whereas 141 
(25.0%) of the participants did not identify working in any facil-
ity; this includes traditional healers, pastors, and community 
workers. Approximately half (279 [50.1%]) had direct contact 
with patients, whereas 177 (31.8%) had indirect contact and 101 
(18.1%) were unlikely to have patient contact.
Ebolavirus Seroprevalence
Overall, 159 (28.1%) of HCWs were GP reactive, 89 (15.8%) 
were NP reactive, 54 (9.5%) were VP40 reactive, and 16 (2.8%) 
demonstrated neutralization. Males had a higher seropreva-
lence compared with females regardless of the test (46.2% vs 
33.3%, respectively; P  =  .01) and showed a significant differ-
ence for GP reactivity (19.7% vs 15.9%, respectively; P < .001) 
and NP reactivity (12.2% vs 8.7%, respectively; P = .02). While 
age was not statistically significant, seroreactivity for all assays 
decreased with increasing age. Among all HCWs, 234 (41.4%) 
were seroreactive for at least 1 assay (Figure  2). The greatest 
overlap of responses was across HCWs who were both NP and 
Table 2. Demographic Information and Antibody Profile for 565 Healthcare Workers in Boende, Democratic Republic of the Congo
Characteristic Total GP1-649 Reactive NP Reactive VP40 Reactive Neutralization 
Sex
 Female 195 (34.5) 31 (15.9) 17 (8.7) 14 (7.2) 3 (1.5)
 Male 370 (65.5) 73 (19.7)a 45 (12.2) 40 (10.8) 13 (3.5)
Age, y
 <25 46 (8.2) 11 (23.9) 7 (15.2) 6 (13.0) 4 (8.7)
 25–34 142 (25.4) 29 (20.4) 9 (6.3) 11 (7.7) 2 (1.4)
 35–44 166 (29.6) 30 (18.1) 20 (12.0) 17 (10.2) 4 (2.4)
 45–54 115 (20.5) 18 (15.7) 16 (13.9) 11 (9.6) 4 (3.4)
 ≥55 91 (16.2) 16 (17.6) 9 (9.9) 9 (9.9) 2 (2.2)
Facility type
 Central office 28 (5.0) 4 (14.3) 3 (10.7) 0 (0.0) 0 (0.0)
 Ebola treatment center 8 (1.4) 0 (0.0) 0 (0.0) 1 (12.5) 0 (0.0)
 Health center 186 (32.9) 28 (15.1) 22 (11.8) 15 (8.1) 5 (2.7)
 Health post 85 (15.0) 24 (28.2) 15 (17.6)a 8 (9.4) 2 (2.4)
 Hospital 92 (16.3) 11 (12.0) 7 (7.6) 6 (6.5) 3 (3.3)
 None 141 (25.0) 32 (22.7) 13 (9.2) 19 (13.5) 6 (4.3)
 Other 25 (4.4) 5 (20) 2 (8.0)a 5 (20.0)a 0 (0.0)
Patient contact
 Direct 279 (50.1) 57 (20.4) 30 (10.8) 29 (10.4) 9 (3.2)
 Indirect 177 (31.8) 29 (16.4) 21 (11.9) 12 (6.8) 4 (2.3)
 Unlikely 101 (18.1) 18 (17.8)a 10 (9.9) 12 (11.9) 3 (3.0)
Data are presented as No. (%). GP and NP reactivity was determined as >2.5 units/mL.
Abbreviations: GP, glycoprotein; NP, nucleoprotein; VP40, Ebola virus matrix protein. 
aP < .05.
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GP seropositive (n  =  29 [5.1%]). Importantly, all neutraliza-
tion-positive individuals were also reactive for at least 1 other 
distinct viral protein (ie, either VP40 and/or NP). Of those who 
demonstrated neutralizing capacity (n = 16), 8 presented both 
NP and VP40 reactivity (50.0%). However, only 3 HCWs were 
seroreactive for all 4 assays.
While no statistically significant differences for serologic 
response were observed across direct, indirect, and unlikely 
patient contact occupational categories, there was considerable 
heterogeneity in serologic response across occupation types 
(Table  3 and Figure  3). The scatterplot presented in Figure  3 
presents the distribution of test results by HCW contact type. 
Among HCWs considered in direct contact with patients, tradi-
tional healers, pastors, and midwives had the highest GP and NP 
seroprevalence (excluding physicians due to sample size, n = 2), 
whereas Red Cross workers had the highest VP40 seroprevalence 
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Figure 2. Venn diagram of overlapping immunoreactivity assay measures in healthcare workers who participated in the Boende outbreak, Democratic Republic of the 
Congo, 2014. Abbreviations: GP, glycoprotein; NP, nucleoprotein; VP40, Ebola virus matrix protein.
Table 3. Antibody Profile by Contact Level (Inferred by Occupation) for Healthcare Workers in Boende, Democratic Republic of the Congo
Occupation Total GP1-649 Reactive NP Reactive VP40 Reactive Neutralization 
Direct
 Doctor 2 (0.7) 1 (50.0) 1 (50.0) 0 (0.0) 0 (0.0)
 Health educator 12 (4.4) 2 (16.7) 0 (0.0) 2 (16.7) 0 (0.0)
 Midwife 42 (15.3) 11 (26.2) 6 (14.3) 5 (11.9) 1 (2.4)
 Nurse 155 (56.4) 24 (15.5) 14 (9.0) 13 (8.4) 4 (2.6)
 Pastor 24 (8.7) 6 (25.0) 3 (12.5) 3 (12.5) 2 (8.3)
 Red Cross worker 18 (6.5) 4 (22.2) 1 (5.6) 4 (22.2) 1 (5.6)
 Traditional healer 22 (8.0) 8 (36.4) 3 (13.6) 3 (13.6) 0 (0.0)
Indirect
 Communication 6 (3.1) 1 (16.7) 0 (0.0) 0 (0.0) 0 (0.0)
 Hygiene 76 (39.2) 12 (15.8) 12 (15.8) 8 (10.5) 3 (3.9)
 Laboratory technician 5 (2.6) 2 (40.0) 0 (0.0) 0 (0.0) 0 (0.0)
 Pharmacy 10 (5.2) 1 (10.0) 1 (10.0) 0 (0.0) 0 (0.0)
 Room attendant 90 (46.4) 15 (16.7) 10 (11.1) 6 (6.7) 3 (3.3)
 Surveillance 7 (3.6) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Unlikely
 Driver 5 (5.2) 0 (0.0) 1 (20.0) 1 (20.0) 0 (0.0)
 Guard 21 (21.9) 6 (28.6) 2 (9.5) 2 (9.5) 0 (0.0)
 Health administration 25 (26.0) 6 (24.0) 1 (4.0) 0 (0.0) 0 (0.0)
 Maintenance 9 (9.4) 0 (0.0) 0 (0.0) 1 (11.1) 0 (0.0)
 Ordinary worker 11 (11.5) 3 (27.3) 2 (18.2) 0 (0.0) 0 (0.0)
 Other 25 (26.0) 2 (8.0)a 5 (20.0) 6 (24.0) 2 (8.0)
Data are presented as No. (%). GP and NP reactivity was determined as >2.5 units/mL.
Abbreviations: GP, glycoprotein; NP, nucleoprotein; VP40, Ebola virus matrix protein. 
aP < .05.
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and neutralizing capacity (22.2% and 5.6% respectively; P < .05). 
HCWs having indirect contact with patient demonstrated simi-
lar heterogeneity across occupations. Those classified as having 
unlikely contacts with patients had the highest GP seropreva-
lence among all groups: health administrators, guards, and other 
(24.0%, 28.6%, and 8.0%, respectively).
DISCUSSION
Using a multiassay approach, our data suggest that at least some 
serological indication of previous ebolavirus exposure and/
or infection among Boende HCWs is higher than previously 
reported [28, 35–40]. A  serological survey conducted during 
Kikwit EBOV outbreak found prevalence of 2.2% among health 
workers and 9.3% in surrounding villages [41]. A recent study 
in Watsa in the northeastern region of the DRC reported an 
EBOV seroprevalence of 18.7% in the local Efe population [42].
 When exploring trends by patient contact, the highest GP 
seroprevalence was observed in the “unlikely” contact group. 
However, within each category there was significant heteroge-
neity. These differences may be explained by the fact that, in an 
outbreak situation, everyone, including guards and administra-
tors, could be required to assist with potentially infected persons 
when regular hospital staff are not able to meet the demands of 
the patients, potentially leading to exposures to bodily fluids, 
sick patients, or community members. This group also likely 
reflects the general population and may indicate that there is 
endemic EBOV exposure in this area. However, overall these 
results most likely suggest that the GP ELISA as a standalone 
test is relatively nonspecific. This may be due to unrelated non-
specific binding, with the high degree of glycosylation in EBOV 
GP lending itself to such nonspecific recognition. Alternately, it 
may be that GP is more sensitive than other viral proteins to the 
presence of cross-reactive antibodies directed against related 
viruses. In contrast, the unique mechanism of ebolavirus entry 
lends itself to highly specific, but possibly insensitive, detection 
of prior ebolavirus infection [43].
HCWs enrolled in this study demonstrated seroreactivity 
to multiple EBOV proteins. Furthermore, we identified that 
16 (2.8%) of HCWs who never reported infection were not 
only seroreactive for at least 1 serologic test but may also be 
able to neutralize ebolavirus if exposed to EVD. This includes 
3 individuals who were seroreactive on all tests and exhibited 
neutralizing capacity: a 52-year-old midwife, a 48-year-old 
administrator, and a 78-year-old volunteer. It is not known 
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whether seroreactivity to assays is related to EBOV exposure 
during the 2014 outbreak—in particular because all HCWs 
included for this analysis participated in the outbreak response 
and reported varying levels of contact with EVD patients and 
biological specimens. It may also be possible that variation in 
antigenic response and neutralization levels may be related 
to asymptomatic or minimally symptomatic infection, which 
would not have been necessarily detected as illness due to EBOV 
[44]. It is possible that some seroreactive individuals could also 
have been exposed to a non-EBOV filovirus.
There were several limitations to this study. We were unable 
to interview every HCW from every health facility in the health 
zone, notably missing HCWs in Lokolia, which is the village 
in which the outbreak was concentrated, due to logistical con-
straints such as impassable roads. We attempted to make our 
study population as diverse as possible by enrolling participants 
in both formal and informal settings, and those who may have 
been displaced from their normal facility to support the outbreak 
response. There may have been some misclassification of specific 
HCW occupations, and patient contact was categorized based 
on occupation type and not recall of contact exposures. In addi-
tion, HCWs may play multiple different roles depending on the 
need of the facility during the outbreak response. We attempted 
to classify them based on their primary position in the health 
facility. Furthermore, all results are based on serologic assays, so 
adjusting the cutoff value can affect the overall results. Thus, we 
explored the range of responses (Figure 3) from each assay and 
used a higher manufacturer cutoff based on the calibration curve 
provided, assuming a higher background rate of cross-reactivity.
Our study highlights the elevated risk of HCWs in DRC 
and exposure to blood-borne pathogens in general. Providing 
adequate training of HCWs to infection control procedures 
and availability of personal protective equipment to reduce 
exposure to bodily fluids of patients they treat before an EVD 
outbreak occurs is ultimately one of the most important strat-
egies to limit the spread of ebolavirus and other blood-borne 
pathogens of both high and low consequence. Furthermore, our 
findings raise additional questions about EBOV exposure, risk, 
and circulating virus in DRC. Currently, there is no serologi-
cal gold standard for ebolavirus serology. Our results highlight 
the need for additional research to better understand the roles 
each protein plays in immune response. Better understanding 
of the significance of EVD seroreactivity and risk factors asso-
ciated with these exposures will improve our ability to design 
and implement locally sustainable strategies to limit exposure 
of HCWs to ebolavirus and other pathogens.
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